This is the current release of the guideline.

All clinical reports and policy statements from the American Academy of Pediatrics automatically expire 5 years after publication unless reaffirmed, revised, or retired at or before that time.

Cord blood transplantation has been shown to be curative in patients with a variety of serious diseases. Physicians should be familiar with the rationale for cord blood banking and with the types of cord blood-banking programs available. Physicians consulted by prospective parents about cord blood banking can provide the following information:

1. Cord blood donation should be discouraged when cord blood stored in a bank is to be directed for later personal or family use, because most conditions that might be helped by cord blood stem cells already exist in the infant's cord blood (i.e., premalignant changes in stem cells). Physicians should be aware of the unsubstantiated claims of private cord blood banks made to future parents that promise to insure infants or family members against serious illnesses in the future by use of the stem cells contained in cord blood. Although not standard of care, directed cord blood banking should be encouraged when there is knowledge of a full sibling in the family with a medical condition (malignant or genetic) that could potentially benefit from cord blood transplantation.
2. Cord blood donation should be encouraged when the cord blood is stored in a bank for public use. Parents should recognize that genetic (e.g., chromosomal abnormalities) and infectious disease testing is performed on the cord blood and that if abnormalities are identified, they will be notified. Parents should also be informed that the cord blood banked in a public program may not be accessible for future private use.
3. Because there are no scientific data at the present time to support autologous cord blood banking and given the difficulty of making an accurate estimate of the need for autologous transplantation and the ready availability of allogeneic transplantation, private storage of cord blood as "biological insurance" should be discouraged. Cord blood banks should comply with national accreditation standards developed by the Foundation for the Accreditation of Cellular Therapy (FACT), the US Food and Drug Administration (FDA), the Federal Trade Commission, and similar state agencies. At a minimum, physicians involved in procurement of cord blood should be aware of cord blood collection, processing, and storage procedures as shown in the table below.

Table. Recommended Procedures for Related and Unrelated Cord Blood Banking

Institutions or organizations (private or public) involved in cord blood banking should consider the following recommendations:

1. Cord blood-banking recruitment practices should be developed with an awareness of the possible emotional vulnerability of pregnant women and their families and friends. Efforts should be made to minimize the effect of this vulnerability on cord blood banking decisions.
2. Accurate information about the potential benefits and limitations of allogeneic and autologous cord blood banking and transplantation should be provided. Parents should be informed that autologous cord blood would not be used as a stem cell source if the donor developed leukemia later in life. Parents should recognize that there are no scientific data to support the claim that autologous cord blood is a tissue source proven to be of value for regenerative medical purposes. The current standard uses of cord blood transplantation are listed in the table below:

   Table: Disease Treatable with Umbilical Cord Blood Transplantation

   Malignancies Bone marrow failure Hemoglobinopathies Immunodeficiencies Inborn errors of metabolism

3. A policy should be developed by cord blood banks regarding disclosing to the parents any abnormal findings in the harvested blood.
4. Specific permission for maintaining demographic medical information should be obtained, and the potential risks of breaches of confidentiality should be disclosed.
5. Written permission for obtaining cord blood should be obtained before onset of active labor.
6. If the cord blood bank is conducting research, an institutional review board must review and approve recruitment strategies and consent forms.
7. Cord blood collection should not be performed in complicated deliveries. The cord blood stem cell–collection program should not alter routine practice for the timing of umbilical cord clamping.
8. Regulatory agencies (e.g., FDA, Federal Trade Commission, and state equivalents of these federal agencies) are encouraged to have an active role in providing oversight of the cord blood program. All cord blood–banking programs should comply with FACT or equivalent accreditation standards.
9. Physicians or other professionals who recruit pregnant women and their families for for-profit placental cord blood stem cell banking should disclose any financial interest or other potential conflict of interest they have in the procedure to their patients.
10. Professionals affiliated with institutions or organizations that promote for-profit placental blood stem cell banking should make annual financial-disclosure and potential-conflicts-of-interest statements to an appropriate institutional review committee that possesses oversight authority.
11. Targeted efforts should be made to recruit underserved minorities (black, Hispanic, American Indian/Alaska Native individuals) in public cord blood– banking programs to extend to them potential treatments afforded other segments of society.

None provided

The type of evidence supporting the recommendations is not specifically stated.

Not applicable: The guideline was not adapted from another source.

2007 Jan

American Academy of Pediatrics - Medical Specialty Society

American Academy of Pediatrics

Section on Hematology/Oncology

Section on Allergy/Immunology

Writing Panel: Mitchell S. Cairo, MD; Joanne Kurtzberg, MD; *Bertram H. Lubin, MD; *William T. Shearer, MD, PhD

Section on Hematology/Oncology, 2005-2006: Stephen A. Feig, MD, Chairperson; James J. Corrigan, MD; Alan S. Gamis, MD; Eric D. Kodish, MD; Peter A. Lane, MD; John J. Hutter, MD; Roger L. Berkow, MD, Immediate Past Chairperson; Mitchell S. Cairo, MD, Past Executive Committee Member

Liaisons: Naomi L. Lubin, MD, American Association of Blood Banks; Edwin N. Forman, MD, Childhood Cancer Alliance

Staff: Laura Laskosz, MPH

Section on Allergy/Immunology, 2005-2006: Paul V. Williams, MD, Chairperson; Bradley E. Chipps, MD; Mary B. Fasano, MD; Mitchell R. Lester, MD; Scott H. Sicherer, MD; Frank S. Virant, MD; Sami L. Bahna, MD; Michael J. Welch, MD, Immediate Past Chairperson

Liaisons: Gary S. Rachelefsky, MD, American Academy of Allergy, Asthma, and Immunology; Todd A. Mahr, MD, American College of Allergy, Asthma, and Immunology

Staff: Pamela T. Kanda, MPH

*Lead authors

Not stated

This is the current release of the guideline.

All clinical reports and policy statements from the American Academy of Pediatrics automatically expire 5 years after publication unless reaffirmed, revised, or retired at or before that time.

None available

None available

This NGC summary was completed by ECRI on April 20, 2007. The information was verified by the guideline developer on April 23, 2007.

This NGC summary is based on the original guideline, which is subject to the guideline developer's copyright restrictions. Please contact the Permissions Editor, American Academy of Pediatrics (AAP), 141 Northwest Point Blvd, Elk Grove Village, IL 60007.